During oral evidence to the Infected Blood Inquiry, Dr Diana Walford stated that it was "a fairly unusual format" to have conclusions already made within an agenda for a committee meeting. This was in reference to an agenda for the Committee on Safety of Medicines Sub-Committee on Biological Products on 13 July 1983.
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Dr Diana Walford